BNET Industries
Generex Biotechnology Corp. (GNBT) is in the Pharma Industry
- Revenue
- Jul 31 2007
- $180.1K
- Profit
- Jul 31 2007
- ($23.5M)
- Market Cap
- Sep 03 2008
- $76.3M
Latest News and Analysis
Four Drug Companies Vying for Diabetes Patients
R.J Steffens submits: The American Association of Diabetes Educators [AADE] released results last week at its high profile 35th Annual Meeting from an innovative new survey entitled the "Injection Impact Report". The report highlights the level of communication between patients and healthcare providers relating to insulin injections and...
Additional Resources
Crystal Research Associates, LLC Issues Executive Informational Overview® on Generex Biotechnology Corporation
NEW YORK, Aug. 20 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational OverviewR (EIOR) on Generex Biotechnology Corporation . The full 64-page report can be found at http://www.crystalra.com/. Generex Biotechnology Corporation ("Generex" or "the Company") is a specialty pharmaceutical company...
Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
BOSTON, July 30 /PRNewswire/ -- Scimitar Equity, LLC issues a review of Generex Biotechnology Corporation , entitled, "RapidMistTM, the Non-Invasive Oral Drug Delivery Platform, Sets the Tone as Best in Class Followed by an Expanding Pipeline and Global Revenues." This review is available at website: http://www.scimitarequity.com/. ...
Generex Biotechnology Featured on FOXNews.com
Generex Oral-lyn[TM], Oral Insulin Product, Described as a "New Tool to Help Diabetics" WORCESTER, Mass. -- Generex Biotechnology Corporation (NasdaqCM: GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, is featured in an interview segment on FOXNews.com concerning Generex Oral-lyn[TM],...
Generex Biotechnology Featured in the Second Flaherty Special Situations
GNBT Leads the 80-Year-Old Marathon Race for Drug Delivery of Oral Insulin with Its Use of Absorption Through the Inner Lining of the Mouth with No Insulin Deposited in Patient Lungs WEST HARRISON, N.Y. -- Generex Biotechnology Corporation's (NASDAQ:GNBT) race to pioneer drug delivery of oral insulin through...
BellwetherReport.com Free Analyst Review for FORM, GNBT, PTRY and NRGN
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased research on the companiesmentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of the...
Generex Awarded Patents In North And South America
Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester,Mass., has received new patents in Canada and Argentina. The Canadian Intellectual Property Office has granted the company a new patent titled, "Mixed Micellar Pharmaceutical Delivery System and Method of Preparation." The patent contains process, formulation and use claims to a mixed micellar pharmaceutical...
Before the Bell Report for Wednesday, March 26th, 2008 - On the Radar:.
M2 PRESSWIRE-26 March 2008-The Micro Cap Opportunity: Before the Bell Report for Wednesday, March 26th, 2008 - On the Radar:C1994-2008 M2 COMMUNICATIONS LTD RDATE:26032008 LOS ANGELES - This morning's On the Radar' Micro Cap trading candidates include, Home Solutions...
STHG, GNBT, JUNI, PLTG - OTCStockExchange.com Stock Alert.
M2 PRESSWIRE-26 March 2008-otcstockexchange.com: STHG, GNBT, JUNI, PLTG - OTCStockExchange.com Stock AlertC1994-2008 M2 COMMUNICATIONS LTD RDATE:26032008 Rochester, NY -- OTCStockExchange.com's "Stock Watch Alert" this morning are Steadfast Holdings Group, Inc. (Pink Sheets: STHG), Generex Biotechnology Corporation (Nasdaq: GNBT),...
Introduces Generex Biotechnology to our Bluechips Portfolio.
M2 PRESSWIRE-13 March 2008-Stock Target Upgrade: Introduces Generex Biotechnology to our Bluechips PortfolioC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 International Stock Targets is a world renowned independent research firm, based in Johannesburg, South Africa. Along with walking investors through the...
Generex Biotechnology Comments on Recent Trading Activity
Rodman & Renshaw Analyst Reiterates Market Outperform Rating and $6 Price Target WORCESTER, Mass. -- Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, commented on trading activity in its stock. The Company believes that the decline in...
Generex Gets Approval For Oral-Lyn Phase Iii Trial
Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester, Mass., a leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that on January 22, 2008 the Ministry of Health of the Ukraine issued an approval letter for the conduct of a Phase III clinical trial protocol for Generex...
Has added Generex Biotechnology Corp. to their watch list.
M2 PRESSWIRE-15 January 2008-The Maybach Journal: Has added Generex Biotechnology Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:15012008 Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing...
New Report Provides a Snapshot Version of Generex Biotechnology Corporation's Performance
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c79219) has announced the addition of Generex Biotechnology Corporation - Company Profile to their offering. Company Profile will assists individual investors, managers and companies in evaluating opportunities, trends, market innovations, and selecting appropriate information solutions in order to make effective decisions. The...
Wall Street News Alert: Breaking News Alert -- AVRG! December 4, 2007
Wall Street News Alert's "stocks to watch" thismorning are: Advanced Resources Group (PINKSHEETS: AVRG), LDK Solar Co.,Ltd. (NYSE: LDK), Generex Biotechnology Corporation (NASDAQ: GNBT) and ZixCorporation (NASDAQ: ZIXI). The current price of gold is now trading around $800 per ounce, which meansinvestors should have Advanced Resources Group (PINKSHEETS: AVRG) on...
Research and Markets: the New Generex Biotechnology Corporation Latest Product Pipeline Report Contains Contact Information, Business Summary, Company Details and Selected Financial Data
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c73920) has announced the addition of "Generex Biotechnology Corporation - Product Pipeline Report" to their offering. The Generex Biotechnology Corporation Latest Product Pipeline Report contains contact information, business summary, company details, selected financial data, detailed product pipeline (including disease...
Wall Street News Alert: DMHN, Monday's Hot Stock to Watch! October 22, 2007
Wall Street News Alert's "stocks to watch" thismorning are: Dynamic Media Holdings, Inc. (PINKSHEETS: DMHN), PMC-Sierra,Inc. (NASDAQ: PMCS), Generex Biotechnology Corporation (NASDAQ: GNBT) andIntuitive Surgical, Inc. (NASDAQ: ISRG). Having recently announced it has secured distribution with several Fortune500 companies, Dynamic Media Holdings, Inc. (PINKSHEETS: DMHN) should onceagain have investors watching...
Stock Market Alerts: Special Alert and Coverage Issued for RBRM! September 19, 2007
Stock Market Alerts' performance stock listincludes: ReBuilder Medical Technologies, Inc. (PINKSHEETS: RBRM), GenerexBiotechnology Corp. (NASDAQ: GNBT), Medtronic, Inc. (NYSE: MDT), Novavax,Inc. (NASDAQ: NVAX). Having just announced yesterday morning it has reached $1.5 million insales, ReBuilder Medical Technologies, Inc. (PINKSHEETS: RBRM) should haveinvestors monitoring the stock closely as the company made...
European patents for Generex
Generex Biotechnology Corporation US has been awarded new patents in Europe and Mexico. The European Patent Office granted the company its fourth European patent titled, "Proteinic Drug Delivery System using Membrane Mimetics." The patent has been validated in nine European countries including the UK, France and Italy. It contains formulation...
Stocks to Watch - GNBT, NUVO, MNRO, VIAC.
M2 PRESSWIRE-22 August 2007-SmallCapReview: Stocks to Watch - GNBT, NUVO, MNRO, VIACC1994-2007 M2 COMMUNICATIONS LTD RDATE:23082007 Generex Biotechnology Corporation (Nasdaq: GNBT) Closed at $1.51. Today announced that its wholly-owned subsidiary has entered into an agreement with the University of Rochester as...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 1983
- CEO: Ms. Anna E. Gluskin
- Employees: 25
Generex Biotechnology is a development stage company engaged in the research and development of drug delivery systems and technology. Since its inception, Co. has devoted its efforts and resources to the development of a platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones and vaccines, which historically have been administered by injection, either subcutaneously or intravenously. Co.'s primary focus is its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator.
Key Competitors
Generex Biotechnology Corp. Company Info
Board of Directors
Ms. Anna E. Gluskin
Chairman
John P. Barratt
Mr. Brian T. McGee
Ms. Nola E. Masterson
Ms. Rose C. Perri
Contact Information
33 Harbour Square
Suite 202
Toronto, Ontario
416 364-2551